First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression or death in adults with multiple myeloma who responded to autologous stem cell transplant (ASCT), according to data from the CASSIOPEIA trial’s second part. These findings, from a pre-planned interim analysis conducted by an independent data monitoring committee, indicate that the Phase 3 trial met the main goals of both its first and second part. As such, the committee recommended unblinding study results, making them known to participants and involved researchers.…
You must be logged in to read/download the full post.
The post Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports appeared first on BioNewsFeeds.